Corrigendum to "Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina" [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234]
Vaccine. 2024 Oct 2:126402.
doi: 10.1016/j.vaccine.2024.126402.
Online ahead of print.
1 Centro INFANT de Medicina Traslacional (CIMET), Escuela de Bio y Nanotecnología (EByN), Universidad Nacional de San Martín (UNSAM), Buenos Aires, Argentina.
2 Centro INFANT de Medicina Traslacional (CIMET), Escuela de Bio y Nanotecnología (EByN), Universidad Nacional de San Martín (UNSAM), Buenos Aires, Argentina; Fundación INFANT, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.
3 Department of Health Services Research and Policy, Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK.
4 Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
5 Fundación INFANT, Buenos Aires, Argentina.
6 Centro INFANT de Medicina Traslacional (CIMET), Escuela de Bio y Nanotecnología (EByN), Universidad Nacional de San Martín (UNSAM), Buenos Aires, Argentina; Fundación INFANT, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina. Electronic address: [email protected].